Robert Marcus
Stock Analyst at JP Morgan
(1.36)
# 3,474
Out of 4,900 analysts
21
Total ratings
47.06%
Success rate
-2.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Overweight | $230 → $285 | $237.76 | +19.87% | 3 | Feb 19, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $12.20 | +514.75% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $178.45 | +48.50% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $100.43 | -50.21% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $117.95 | -87.28% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $31.02 | +83.75% | 2 | Jul 29, 2020 |
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $230 → $285
Current: $237.76
Upside: +19.87%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $12.20
Upside: +514.75%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $178.45
Upside: +48.50%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $100.43
Upside: -50.21%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $117.95
Upside: -87.28%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $31.02
Upside: +83.75%